Balancing speed, science and regulatory requirements in oncology drug development
- 16 September 2022
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 28 (11), 2234-2235
- https://doi.org/10.1038/s41591-022-01975-0
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Clinical Holds in Early Oncology Drug DevelopmentPublished by Cold Spring Harbor Laboratory ,2022
- The clinical development of antibody–drug conjugates — lessons from leukaemiaNature Reviews Clinical Oncology, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modelingnpj Systems Biology and Applications, 2020
- Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by ExampleClinical Cancer Research, 2016
- Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer ChemotherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006